impact medicines feel better live longer corporate social responsibility report corporate responsibility integral part business inherent mission company glaxosmithkline makes significant positive contribution society around world medicines healthcare products research develop manufacture sell contents global challenge valuing people scope business environment health safety contribution society business ethics integrity medicines developing world management csr community investment web references research development impact medicines cover story although generation separates bettina bartels son philippe able lead active lives despite suffering asthma story found annual review report dr vincent mcgovern gives perspective asthma management patient doctor annual report annual review corporate social responsibility reportduring invested total million global community activities product donations charitable contributions uk company donated million albendazole tablets worth million countries support prevention lymphatic filariasis increased shipments combivirhivaids treatment preferential prices developing world nearly million tablets million worked companiesto establish new industry principles conduct clinical trials communication clinical trial results surveyed managers views gsks spiritand culture global challenge responsible behaviour types products must improve peoples lives ensure organisations including multinational profitable sustainable future business companies governments charities high also understand much public agenda stimulates considerable profit make matters stakeholders including debate last year first review corporate employees want know make profit social responsibility covered gsks reassured sound ethical basis first year new company set business commitment connecting business decisions ethical social environmental concerns could run business effectively without talking listening many groups report covers activity business impacts discussion stakeholders cover issues generated significant part everyday work much two interest stakeholders made good way relationship views expectations progress year including developing indicators stakeholders directly affect us enable us show progress addressing issues continue build consult widely formally less formal steps increase transparency ways diversity stakeholders example operations way expect give patients customers healthcare professionals stakeholders confidence value governments nongovernmental organisations business feel shareholders inevitably gives rise different sometimes conflicting demands us consider corporate responsibility integral part continue constructive engagement business inherent mission guide us running successful business company gsk makes significant positive contributes meeting needs society contribution society around world medicines vaccines healthcare products research develop manufacture sell sir christopher hogg jp garnier chairman chief executive officer glaxosmithkline researches develops manufactures markets medicines consumer health products around world scope business employees operating countries research development centres countries production facilities countries key impact areas rd diseases medicines community ethical issues developing world developing world investment rd continuing commitment facilitating access improving quality considering questions find preventions medicines improving life underserved people arise research treatments particularly health education developed development new hivaids malaria tb partnerships developing world medicines vaccines glaxosmithkline scope business glaxosmithkline operates pharmaceutical commercialise support effective marketing consumer healthcare sectors making prescription prescription medicines vaccines delivery systems medicines vaccines overthecounter medicines treatment prevention human disease oral care nutritional healthcare products employ staff rd rd sites worldwide business founded primarily research development discover develop register portfolio products ranges tablets toothpaste inhalers capsules make different pack sizes presentations financial profile network manufacturing sites countries employ sales manufacturing related support functions trading profit year produce four billion packs businessperformance delivered sale countries rd spend pharmaceutical industry highly regulated sales every stage discovery sales marketing closely controlled stakeholders many usa pharmaceuticals expectations different europe pharmaceuticals international pharmaceuticals thus size complexity make challenging consumer healthcare business raises many questions information financial performance available main impacts annual report accounts society manage described report developingour supporting caring business employees human rights environment ethics attracting rewarding respecting rights using resources efficiently ensuring employees motivating people safe interests minimising negative understand implement healthy workplace affected involved environmental impacts code conduct business policies ensuring ethical business practices contribution society main activity company developed countries availability effective antibiotics vaccines longer develop medicines including vaccines expect children risk infectious make valuable contribution diseases challenge extend advances developing countries society medicines save lives number diseases research relieve suffering treat often produced major advances continues grow prevent disease improve quality however still much challenge company continue meet societys life patients carers expectations developing innovative medicines enable people live longer healthier lives also enable people carry lives often reduce cost access medicines also want play part improving managing illness healthcare people currently limited access medicines programmes developing countries set positive effect medicines us helping improve access peoples lives one factors medicines lowincome senior citizens motivates employees nature disabled lack prescription drug coverage gives opportunity make public private insurance programmes difference health millions people late gsk launched orange cardsm around world offers savings companys prescription medicines first programme changing expectations kind us participants required simply advances medicine society changed present card pharmacists receive expectations healthcare diseases savings addition last year gsks patient devastating impact controlled assistance program provided medicines worth improved healthcare management million low better medicines vaccines led income patients us many people developed world take good medical insurance health granted following positive response orange card example generation ago polio one patients doctors companies gsk six worlds feared infectious diseases thanks pharmaceutical companies launched joint worldwide vaccination initiative coordinated scheme together rx cardprovides world health organizationand major eligible senior citizens disabled us contribution vaccines business global single easytouse card receive savings elimination polio sight prescription medicines seven companies involved gsk opening door programmes real impact significant savings estimated lives disadvantaged people across us million americans make tremendous difference lives many people tommy thompsonus secretary health human services launch orange card case study asthmarelated deaths hospital admissions declined incidence asthma growing asthma remains major health issue worldwide focus matters patients concentrating quality life development dr vincent mcgovern general doctors perspective gp also asthmatreatments practitioner belfast uk gives asthmatic find asthma really satisfying condition perspective asthma management treat common million sufferers fsventolinbronchodilator patient doctor uk practice per cent relieves breathlessness hours per dose asthmatics mildtomoderate disease aim patients perspective management achieve total control symptoms using fsbecotidebeclovent corticosteroid reduces asthma changed dramatically last current treatments giving good quality inflammation lungs years child wanted play football life standard patient care getting leads asthma symptoms play goal rounded shoulders higher either specialised units oneto fssereventbronchodilator blue inhaler every pocket remember one consultations nurses doctors asthma relieves breathlessness hours per dose sleepless nights emergency visits area national treatment guidelines doctor inhaled steroids became available adopted major impact fsflixotideflovent corticosteroid effectively took away sleepless nights development disease management reduces inflammation new treatments made huge impact lungs leads asthma symptoms life still asthma well controlled last years rd organisation preventative treatments certainly dont notice produced improved medicines treat asthma ftodayseretideadvair bronchodilatorcorticosteroid nobody else either better ways taken advances first asthma product vital enabling healthcare professionals relieves breathlessness hours per dose reduces provide everimproving patient care however inflammation leads asthma still causes suffering even death asthma symptoms one easy use device continue research aim improving lives growing number people affected disease developing countries millions people lack access basic healthcare services lifethreatening diseases tuberculosis malaria hivaids contributing healthcare crisis medicines developing world global community must provide political significant mobilisation additional resources spirit partnership see improvement healthcare quality life across developing world glaxosmithkline making vital contribution ddw development pipeline end healthcare developing countries preclinical action three areas investing research activity phase phase ii phpahsae siiei iii marketed development rd targets diseases vaccines hiv hepatitis e psn epunmeuomnioaneiae havrix hepatitis particularly affecting developing world dengue fever rotavirus paepdaieadtriiactric engerix b hepatitis b meningitis b twinrix hep b preferential pricing antiretrovirals malaria infanrix diptheria tetanus n meningitidis acellular pertussis antimalarials vaccines community tritanrix diptheria tetanus wholecell pertussis investment activities partnerships polio sabin polio priorix measles mumps foster effective healthcare made rubella typherix typhoid significant advances key hiberix haemophilus influenzae type b areas hiv nnrti integrase inhibitor ziagzeiangeepniveipr ivir retrovir protease inhibitor comcobminbaitnioantion epivir combivir rd diseases developing world ziagen trizivir research diseases developing world agenerase protease inhibitor ddw particularly important address unmet needs minimise intrinsic threat malaria cda tafetanfoeqnuoiqnueine malarone halfan infectious diseases resistance developing lapdap existing treatments tb sitamaquine oxibendazole sitasmitaamquaiqnueine zentel dedicated ddw group created within oxiboexinbdeanzdoalezole gsks rd organisation ensure focus registered yet marketed area projects prioritised primarily socioeconomic public health benefits rather rd diseases primarily affect developing commercial returns ddw research world malaria differs important respects focused dedicated facilities tres cantos efforts aimed diseases developed spain see world market also exists hivaids lack commercially viable market ddw treatments believe gsk industrys extensive means publicprivate partnerships essential portfolio ddw rd projects marketed major companies gsk provide products company technological development manufacturing undertaking rd prevention treatment distribution expertise public sector partners three world health organizations help fund development costs ensure priority diseases developing world hivaids new medicines vaccines get people tuberculosis malaria gsk focuses need partnership approach encourages three diseases also industry leader rd accelerates products uptake collaborating external partners want developing world use specialist infrastructure expertise longterm commitment number supply arrangements arvs type ofcustomer bearing fruit hopeful able launch several new products relevant ddw next five years q q q q q q q q q q key employers ngos aaiaccelerating access public hospitals govt non aai initiative maintain broadly current level human lapdapresults successful partnership financial resources dedicated ddw gsk world health organization proportion total rd investment university liverpool london school work assiduously partners appropriate hygiene tropical medicine uk ensure promising ddw drug made department international development dfid available patients rapidly possible rd first product development process lengthy risky however long directly sponsored dfid term commitment bearing fruit hopeful able launch several new preferentialpricing products relevant ddw next five years gsk recognises responsibility make products affordable possible poorest seen notable progress countries offered vaccines public hivaids first human clinical trials health programmes significant discounts hiv candidate vaccine commenced february years set single sustainable notforprofit collaboration us governments national preferential price antiretrovirals institutes health hiv vaccine trials network arvs antimalarials wide range conjunction partners gsk continues customers least developed countries support hiv clinical trials developing countries subsaharan africa total countries including africa purpose trials customers include public sector notforprofit assess use antiretroviral therapy treatment ngos aid agencies un agencies international prevention mothertochild hiv transmission purchase funds global fund fight resourcepoor settings patients form aids tb malaria also extend offer form part hiv collaborative studies three notforprofit prices arvs employers thousand patients included subsaharan africa provide care treatment dart trial developing antiretroviral therapy workplace clinics similar arrangements uganda zimbabwe coordinated uk special access packs medical research council gsk committed contributing health improvements sustainable manner set progress malaria october preferential prices arvs antimalarials submitted regulatory application levels cover direct costs uk medicines control agency mca lapdap make profit way offer chlorproguanildapsone treatment prices long patients need treatment life threatening type malaria mca approval important step making lapdap available across africa great need new malaria treatments stnemegnarra ylppuscumulative shipments combivir tablets excluding diverted product q q q q q q q q pledged pass cost efficiencies additionally started smallscale shipments developing world increase shipments wider range preferentiallypriced instance september reduced products five pilot projects notforprofit preferential prices hivaids partnership ngos tanzania uganda nigeria medicines per cent antimalarial zambia malawi projects designed medicines per cent assess impact preferential pricing broader range products end secured arrangements supply preferentiallypriced arvs community investment programmes countries includes arrangements made wide range partnerships arrangements wide developing world focus health range stakeholders including governments education programmes underserved communities ngos public hospitals employers around world gsk invested heineken anglo american million public health programmes commenced partnerships partners range world health result increased shipments combivir organization world bank local schools developing world million tablets communitybased organisations possible nearly million tablets ensure programmes sustainable equivalent million daily doses repeated communities similar needs figures exclude product destined patients africa diverted back europe programmes comprise major initiatives public victims trade hivaids patients africa health support education product donations beneficiaries illegal importers support employee involvement activities gsk introduced special access packs make public health programmes example include illegal trade difficult look regulatory authorities customers also take measures global alliance eliminate lymphatic prevent diversion filariasis gsk key partner global effort eliminate lymphatic filariasis lf also known gsks ability provide preferential prices elephantiasis disabling disfiguring developing world requires sustainable framework disease currently affects million people commitment preferential pricing must threatens one billion combined commitments others prevent poorest nations world product diversion avoid referencing developed country prices preferentiallypriced medicines clearly diversion threatens framework snoillim deppihs stelbatour partners range world health organization world bank local schools communitybased organisations gsk founding member partnership positive action programme gsks includes world health organization ministries international programme hiv education care health lfendemic countries community support backed international organisations public private academic programmes countries activities funded sectors gsk donates antiparasitic drug albendazole positive action support twoyear live let one three drugs used stop transmission live world aids campaign launched unaids disease anticipated year life world aids day example positive action programme commitment build funded studies international center estimated six billion tablets countries join research women conducted ethiopia addition provide significant financial resources tanzania zambia confirmed societal staff expertise support coalitionbuilding discrimination based hiv fuels spread advocacy research community mobilisation aids positive action also announced funding educational initiatives new community initiatives kenya mexico th international aids conference fourth year programme million held barcelona july positive action tablets worth million donated contributed support attendance countries bringing total number albendazole participation community representatives tablets donated date million grants totalling underresourced regions also made huge mobilisation effort required fight lf gskfrance foundation supports exemplified health workers programmes prevent risk vertical volunteers sri lanka worked together transmission hiv provide medical care deliver preventative medicines million people monitoring treatment improve access single day july quality care people living hiv foundation supported programmes involving people part four year million commitment eight african countries african malaria partnership amp november three organisations selected share grants totalling million three years amp programme gsk funding behavioural development initiatives combat disease kills one million people every year total nearly two million people reached programmes seven countries involved snoillim glaxosmithkline much proud improving healthcare developing world drug distribution research development community activities worlds attention focused private companies governments work together constance carrinodirector office hivaids usaid lf elimination programme million albendazole tablets donated date years key estimated patients treated tablets donated mcase study gsks research diseases developing world ddw centred dedicated rd facilities tres cantos spain addition hivaids vaccines rd programmes gsks tres cantos site houses major elements tres cantos group fully integrated rd highthroughput screening activities rest gsks rd order ensure gsks commercial operations spain bring relevant skills technologies however also concentrated resources bear achieve success developing ddw drug research tb malaria efforts discoveries regard gsks advantages long history gsk dedicated scale networks key external facilities site fulltime research partners important staff committed solely ddw particular access gsks worldwide clinical well centres tb malaria focus ideas development organisation vital effective drug candidates treating neglected conduct clinical trials however ddw group diseases developing world pursued tres cantos associated ddw drug opportunistically development existing development team london also call gsk drug candidates diseases continue gsks expertise staff many areas screening preclinical development tres cantos ddw scientific staff provide regulatory affairs wide range skills including chemistry biology toxicology needed better understand disease targets identify novel drug candidates development concentration resources skills maximises ability discover new medicines ddw total value community investment activities million project hopeairlift gsk antibiotics tajikistan product donations humanitarian relief reached countries community investment focus glaxosmithklines community investments improving health education programmes extend developed developing world efforts targeted improving quality life people underserved communities work partner organisations around decade steady immigration refugees world ensure right blend afghanistan member partnership expertise applied programmes quality medical donations gsk fully endorsed select partners best agreed follow guidelines experience skills initiative drug donations programmes selected basis community need potential impact public health programmes directed gsks commercial business increase areas specific diseases prevalent sales products fund programmes means hivaids community programme measurable sustainable replicable positive action global reach effort work closely partners ensure eliminate parasitic disease lymphatic filariasis success focused endemic countries developing world african malaria partnership worldwide community contribution directed continent bears greatest gsks community investment charitable burden disease see contributions totalled million million related companys patient developed world community assistance program financially disadvantaged programmes support communities need patients us corporate regional public share programme us canada health humanitarian relief programmes aim targets health elderly racial ethnic minority serve communities greatest needs meet communities providing monetary awards local needs gsk operating companies also support innovation sharing best practice reducing numerous local community programmes health inequality among vulnerable groups gsk product donations humanitarian relief made charitable partner organisations experience delivering humanitarian relief fund programmes charities decide product measurable sustainable donations needed work governments recipient countries ensure replicable work arrive safely distributed appropriately example donation almost half million closely partners treatments antibiotic augmentinwas part ensure success airlift vital medicines tajikistan october organised project hope already struggling overcome effects civil war tajikistan challenged international business leaders forum award international corporate citizenship made gsk phase programme provides hygiene education school children charity plan uk impressed gsks approach partnership willing consult local communities develop materials easy use relevant local culture save childrens lives marie stauntonexecutive director plan international phase programme making real difference health wellbeing local communities excellent example positive role business society robert davieschief executive international business leaders forum method giving including uspatient assistance program uk part broad commitment science type programme education committed million excluding uspatient assistance program four years fund inspire innovative scheme public health programmes including lf postdocs research education programme boost science education schools product donations supports selected schools applying become corporate regional programmes science colleges uk governments specialist schools programme local programmes cash gsk provides support many different ways example donating money products inkind donations office furniture computers surplus laboratory equipment product donations valued wholesale acquisition cost relates price gsk charges wholesalers warehousing chains retail price kind company follows london benchmarking groupmodel recording community investments recognised model provides standard basis companies manage report commitments community product case study wide range seriously debilitating life threatening diseases thrive poor living conditions found many countries developing world africa alone million children die year diarrhoeal disease gsk launched initiative called phase containers handwashing pit latrines personal hygiene sanitation education refuse pits provide hygiene education school children aim reducing diarrhoea evaluation kenyan programme shown related disease deaths associated result phase children better poor hygiene understanding causes diarrhoea worm infestations know ways phase started partnership amref african prevent infection teachers seen improvements medical research foundation operates school attendance report children kenya nicaragua peru gsk much cleaner take better care committed million rollout latin personal hygiene data one class show america gsk works childfocused percentage children knew washing development charity plan international kenya hands going toilet could prevent worms children schools benefiting increased per cent phase basic education nicaragua per cent afterwards reach primary school children peru success programme kenyan government incorporated phase phase empowers children families national curriculum increasing take responsibility health likelihood benefits available sanitation communities around participating parts kenya schools also benefited homes understand need balance benefits patients gain new medicines risks ethical considerations relating new technologies research development glaxosmithkline aims produce safe effective medicines vaccines benefit patients addressing unmet medical needs need use recent advances science technology understand diseases identify test drugs unable take advantage encourage staff devise alternative approaches three rs advances patients best animal research internal animal welfare animal research treatments understand concerns awards gsk sponsors largest european award technological advances rd process field gsk laboratory animal welfare welcome informed debate prize inspections national regulatory authorities acknowledge high standards care reduce rd process highly regulated wherever compliance facilities ensure operate scientific advances raise new issues meet best practice us uk animal facilities work closely regulators policy makers accredited association assessment stakeholders develop new refined accreditation laboratory animal care standards internal standards working extend facilities systems ensure comply exceed refine guidelines regulations legal requirements believe best way address public interest animal research foster greater essential role animal research knowledge understanding facts basic research using animals vital furthering also believe effective way understanding human disease animal help combat climate fear intimidation studies also provide essential bridge promoted animal extremist groups replace characterising potential new medicines vaccines therefore provide information support rational laboratory learning effects public debate actively participate discussions people law must assess drug safety host tours animal facilities animals starting clinical trials possible also welcome government committed three rs reduce refine actions protect staff laboratory animals reducethe number animals used medicines rd replace animal studies set stringent standards research collaborators extremist actions minimum possible obtain internally external contractors visit schools discuss relevant ethical issues meaningful validated results ensure gsk staff conducting animal studies example involving uk pupils thoroughly trained discussions school year refineanimal experimental procedures avoid minimise information gsks use animals research available pain discomfort reduce number animals used research website maximise information wherever without compromising safety obtained study volunteers patients clinical trials animal obliged law seek much information possible animal study number animals used assess drug safety replacethe need animal studies developing laboratories therefore remained essentially validating alternative approaches animals starting constant last eight years spite wherever feasible significant increase rd activity see chart clinical trials use animals humanely using example noninvasive imaging see rapid technological advances provided us tools make major progress fight disease testing new medicines clinical trials principles reflect importance independent gsks aim develop medicines vaccines institutional review boards ethical review benefit patients reflected priority give committees protecting patients volunteers protecting interests healthy volunteers involved clinical trials gsk fully supports patients take part clinical trials guidelines reiterate need obtain regulatory authorities rigorously scrutinise genuinely informed consent clinical initiation conduct clinical trials related procedure undertaken obligation gsk activities need respect rights dignity extends include acquiring using human safety wellbeing clinical trial participants biological samples tissues dna enshrined declarations guidelines produced principles also summarise safeguards world medical association world health industry including gsk adopts ensure organization council international reimbursement patients external clinical organisations medical sciences council investigators expenses inappropriate europe international conference inducement participate clinical trials bias harmonisation ich government bodies results reported regulatory authorities gsk fully complies relevant regulations requirements financial disclosure protect national requirements guidelines public interest area ich good clinical practice regulations guidelines periodically reviewed revised principles articulate industrys gsks ensure fully address interests practice seeking publish meaningful results patients gsk actively contributes discussions controlled clinical trials regardless outcome basis extensive global experience timely manner includes giving clinical trialists appropriate level access raw data last review summarised rigorous interpretation procedures ensure patient safety privacy medical information recently strengthened procedures avoid information sent gsk external investigators would enable us identify trial participants however know conduct clinical trials raises ethical issues therefore worked companies establish new phrma principles conduct clinical trials communication clinical trial results ecnis egnahc change rd activity compared change number animals used gsk years figures normalised levels key animals used rd activitycase study noninvasive imaging techniques magnetic resonance imaging mri provide new relevant scientific information ways previously possible refining research using animals serial mri allows respiratory biologists study lung studying disease effect drug inflammation rats mimics aspects period time animals would previously human asthma animals scanned humanely killed organs minimising discomfort several weeks allows removed microscopic examination chronic inflammatory responses timepoint mri enables animal studied beneficial effects standard repeatedly assessed timepoint new drugs measured mri approach number animals used reduced typically requires animals study would require undertaken using moreover get detailed information conventional microscopy approaches progress disease frequent scanning would possible every timepoint similar approaches taken needed separate group animals resource research areas neurology psychiatry intensive technologies microscopic cardiovascular diseases well preclinical examination importantly animal often safety assessment cumulative beneficial impact used control statistical power studies enhanced even using far number animals used data quality fewer animals therefore significant gsk employs people operates countries valuing people people greatest single source competitive advantage company glaxosmithkline believe attracting retaining motivating best people foundation future success committed providing opportunity survey results generally positive employees meaningful showing managers take great pride challenging work pursuit goal part gsk example overwhelming improve quality human life enabling support statements people people feel better live longer department show commitment performance integrity department focused organisation last year reported principles underpin sense urgency would gladly refer approach people management range good friend family member gsk programmes designed deliver global employment findings show managers human resources strategy pleased believe gskspirit reflected way report progress made set others working day day able intend future measure performance issues diversity results also raised important areas development included concerns whether gsk culture people able perform full potential gsk great emphasis placed extent managers able act coaches must achieve company also support development degree staff deliver achievements culture summed involvement decisions affect work gsk spirit defines qualities issues addressed gsks corporate expect employees embrace executive team example programme put place reduce complexity bureaucracy performance integrity company streamline processes help free entrepreneurial spirit managers best work focus innovation sense urgency passion achievement survey results developing gsk culture critical enabling generally positive people reach potential best work therefore carried survey showing managers managers assess well spirit take great pride culture adopted sought views experience working gsk including part gsk managers considered done well areas needed work fundamentally committed principles equality opportunity equal treatment diversity ethnicityofusemployeepopulation diversity business imperative gsk committed principles equality opportunity equal treatment aim workforce working environment reflects diversity background culture beliefs people characteristics communities colour operate therefore embedding values diversity total us employees equal treatment key business processes employees means diversity measures included manager employee training external human rights recruitment internal appointment processes gsk believes human rights issues performance assessments pay reviews lead example thereby influence succession planning developmental assignments behaviours practices others clear demonstration values effective customers stakeholders includes contribution made pursuing policies development measures reach targeted operations respect rights customers outreach programmes specific interests affected involved patient groups advertising reflects business gsksupports committed many communities serve upholding united nations universal declaration human rightsand core labour standards believe diversity strategy show clear set international labour organization progress baseline figures report year see report changes annually carried internal review demonstrated wherever operate employer believe complying global senior management population universal declaration human rights gender men women core conventions international labour organization according guidelines bands b multinational enterprises set oecd bands c conducted head human resources bands c country review also used total build awareness understanding human rights issues corporate executive team vicepresidentssenior vice presidents director level manager level also year began put place binding requirements ensure major exception us see ethnicity chart contractors suppliers adopt gsks standards meaningful data ethnicity human rights core labour standards employees different ways ethnic groups described different countries cases legal restrictions collecting data case study promotion diversity within gsk powerful effect way think needs customers ensuring medicines benefit widest building success cultural awareness training possible number patients heart extended sales groups across us mission enable people feel approach also used better live longer one gsks gsks us pharma marketing departments general pharma sales marketing units increase multicultural awareness us made key business objective understanding relating brands improve access gsk medicines patients ethnic minority communities addition multilanguage patient education programme supporting us unit operates part southern california healthcare professionals raising awareness particularly high population vietnamese diseases disease management among groups koreans armenians central americans limited command english disease education mexicans materials asthma migraine rhinitis depression provided gsk sales sales teams specific training cultural representatives number languages including awareness improve understanding spanish chinese vietnamese korean russian customers particular needs result doctors better able use gsk products benefits individual patients communities gsk comprehensive programme characterise physical chemical properties environmental fate effects occupational health effects products chemical processes environment health safety responsible global citizen glaxosmithkline strives preserve environment protect health people work us comprehensive framework although many contractors sites environmental health safety programmes work direct supervision safety provide structure approach important employees apply based ehs standards apply standards monitor health without exception sites around safety external contractors working gsk world lost time injury illness rate similar rate employees environmental sustainability basis environmental programmes addressing improve ehs performance strong potential adverse impacts wastes ehs management systems programmes place approach achieving sustainability focus four examples given improving efficiency manufacturing processes minimise materials used ehs information products processes waste generated optimise use gsk comprehensive programme renewable raw materials characterise physical chemical properties environmental fate effects occupational occupational health safety programmes health effects products chemical focus protecting enhancing health processes information helps us safety employees reflecting value place people fdesign operate production control systems protect employees improvement targets communities operate ehs performance targets set finform employees public baseline performance first full year hazards materials help understand gsks operations achieved handle safely end environmental emissions companywide targets set one gsks dry powder devices consolidating individual site targets health safety target reduce lost time injuries illnesses per cent year baseline rate lost time injuries illnesses hours worked preliminary data indicate meet target year final verified results website wwwgskcom enilesab fo contract manufacturers decommissioning sale gsk spent gsk uses contract manufacturers number million date expects spend countries supply certain products local million remediation existing sites markets cases specialist processes designing implementing remediation technologies integral part projects work government agencies product supply chain work local communities use best technologies prevent adverse events ensure reliability available clean land allow return product supply ensure companies use community parklands managing ehs risks impacts responsibly conformance gsk requirements legislation sites land contaminated assessed programme ehs audits due past storage disposal practices including conducted ehs global audit team poor containment accidental releases commercial disposal sites global standards audits cover general management ehs systems place cover phases control key risks impacts areas waste management designed prevent future improvement highlighted contract incidents could contaminate land manufacturer progress monitored key contract manufacturerssuppliers assessed environmental performance gsks heritage companies realised benefit ozone depletion chlorofluorocarbon cfc setting targets improve environmental elimination metered dose inhalers mdis performance improvement projects started common way asthmatics receive continue future chart medication however many mdis use illustrates improvements already achieved propellants cfcs ozone depleting air emissions voc wastewater discharges cod global warming gases hazardous waste disposed three years leading gsk baseline currently gsk extensive plan containing milestones eliminate cfcs recent performance data ehs mdis progress excellent per cent targets available website actions completed first time since transition began gsk manufactured examples environmental million noncfc mdis launched first performance improvements noncfc mdi us cfcfree ventolin coupled offering wide choice dry powder devices confident ability transition away cfcs therefore believe montreal target protocol essentialuse exemption allows manufacture cfcs salbutamolalbuterol active ingredient ventolin mdis marketing salbutamolalbuterol mdis containing cfcs longer necessary year contaminated land figures normalised sales currently studying actively cleaning key vocvolatile organic compounds emitted air sites classed contaminated land codchemical oxygen demand wastewater also remediating number former hwdhazardous waste disposed manufacturing sites preparation case study innovative approaches delivered excellent safety record construction gsks new horlicks plant india gsk recently completed building new new approach major greenfield factory sonepat north india meet site construction project india historically growing demand country horlicks projects type involve high level one gsks popular nutritional drinks attention health safety formal safety training common result project involved construction initiatives accomplished partnership personnel total million hours construction management subcontract work years peak companies sonepat returned one best workers site one time workers losttime accident figures seen projects within site less days ensuring gsk legacy companies benefits changing workforce made aware safety health safety planning demonstrated health issues significant challenge immediately improved course project last million hours health safety given priority worked without losttime injuries illnesses construction planned appropriate lasting benefit project future programmes put place site application lessons learned creating included providing hour site health facility safety culture injuries illnesses could treated early workers need leave site treatment project ehs initiative award induction training new workers emphasised safety sponsored chief executive officer inspectors monitored highrisk areas site selected panel judges representing weekly talks safety topics special training academia government ngos gsks board programmes scaffolders held directors high standards honesty integrity vital success businessperformance integrityis principle aim live work gsk business ethics integrity glaxosmithklines code conduct lays principles company values employees apply daily work responsibility employee implement code sustain trust confidence gsks stakeholders corporateethicsand compliance framework includes risk oversight gsk committed operating within law compliance council well sector highest ethical standards healthcare business unit risk management compliance industry highly regulated discovery boards risk oversight compliance council development manufacturing marketing boards assist identification mitigation medicines complex processes thus aim risks provide guidance risk management build adherence high standards everyday initiatives corporate business unit levels management processes activities risk oversight compliance council reports formal company polices procedures set audit committee gsk board expected standards conduct effective chief executive officer also report communication training standards corporate executive team reporting line followed regular monitoring periodic review audit committee provides mechanism work output critical lawyers bypassing executive management irregularities compliance officers closely involved establishing ever identified communicating standards gsk emphasises personal responsibility employees line gsk risk management compliance framework managers ensuring employees observe principles everyday work support corporate social audit committee gsk board responsibility committee undertake ethics training computer based sessions interactive discussions ceo corporate ethics compliance function gsk responsible supporting development cet businessandfunctionheads implementation practices facilitate employees compliance laws company risk oversight compliance council rocc policy specialist compliance officers support main operations pharmaceuticals consumer healthcare rd manufacturing business unit functional risk management compliance boards internal control framework integrates ethics business functional groups compliance daytoday management group framework supports line potential risks riskgenerating activities functions management identification mitigation significant risks among potential compliance failures confidential tollfree lines compliance officers available employees report concerns gsk policies gsk code conduct gsk policies available internal website guide business conduct published internal website support employees understanding implementation standards guide summarises policies explains companys expectations business ethics good business conduct notification systems confidential integrity help lines compliance officers available employees report concerns feel dealt adequately normal management system help lines available employees uk us reaching half total gsk workforce employees take advantage email access compliance officer report concerns confidential post office box maintained corporate ethics compliance help lines primarily used consultations employees ask questions result number callers inquiries received compliance officers tends increase response training changes issuance new policies activity levels reflect greater awareness policies legal requirements rather trends unacceptable practices response levels indicate existence systems purpose well understood case study senior managers gsk expected lead example working line code conduct gsk policies supporting staff ensure understanding fall people supervision received responsibility gsk introduced copies access gsk code certification process around world conduct gsk policies understand managers vicepresident level responsibilities certification requires managers sign around managers vice statement confirming awareness president level completed certifications obligations implement company code believe process support conduct policies includes confirming dissemination awareness gsk ethical standards code conduct fthey know personally obliged comply importance thousands gsk employees applicable laws regulations gsks course daily activities must corporate local policies procedures work line law gsk policies fthey accept responsibility put place appropriate measures ensure people supervision aware obligations management csr contributing improving peoples lives responsible corporate citizen integral established part business practice corporate social responsibility csr also believe stakeholder discussion activities including covered report anything requires specialist knowledge best managed appropriate functions undertaken expertise hence organisation rather central team representatives discuss issues directly department believe effective expressed interest concern approach managing issues central coordination means broader remain integrated part everyday issues brought attention operation business crossfunctional team facilitate policy development implementation gsk process place identifying evaluating communication crossfunctional team managing significant business risks established beginning ensure includes reputational corporate responsibility comprehensive coordinated approach issues risk management process accords team made representatives key turnbull guidance formal risk assessment business areas ensure policies place updated least year risk oversight mechanisms exist implementation compliance council see coordinates monitoring representatives also contribute internal control risk management activities reporting progress report ensure effective management significant risks ways example conference presentations website year csr committee non executive board members gave advice year crossfunctional team developed report activities specific input indicators support reporting key issues approach community investment determining indicators aim strike environment health safety human resources balance desires stakeholders policies including diversity human rights issues greater transparency operations realities costs running business crossfunctional management gsk board csr committee csr activities ceo cet member csr coordination global government reporting affairs public policy rd diseases medicines ethical issues caring business developing supporting community developing developing rd ethics human rights investment world world environment employees web references corporate website found wwwgskcom websites cited report wwwgskcomsersercsrpdf wwwgskcomcommunity wwwpolioeradicationorg wwwprojecthopeorg wwwgskcompressarchivepresshtm wwwpqmdorg wwwtogetherrxcom wwwgskcompressarchivepresshtm wwwgskcomaboutdevelopingworldhtm wwwicacuktemplatestextaspp wwwniaidnihgovfactsheetshvtnhtm wwwcorporatecitizenshipcoukcommunitylbgasp wwwwhointinfprenprhtml wwwrdsonlineorguknewshtml wwwgskcomaboutnfppricingguidehtm wwwaaalacorg wwwgskcompressarchivepresshtm httpsciencegskcomaboutanimalresearchhtm wwwgskcomcommunityabouthtm wwwphrmaorgpublicationsquickfactscfm wwwgskcomfilariasisindexhtm wwwunorgoverviewrightshtml wwwgskcompositiveactionindexhtm wwwiloorgpublicenglishstandardsdecldeclarationtextindexhtm wwwgskcompressarchivepresshtm wwwoecdorgpdfmmpdf wwwgskfrgskfondmphtml wwwgskcomserserehspdf wwwgskcommalariaindexhtm corporatesocialresponsibility committee donald mchenry sir christopher hogg nonexecutive director glaxosmithkline sir christopher nonexecutive chairman chairman corporate social responsibility glaxosmithkline nonexecutive chairman committee mr mchenryis distinguished reuters group plc member supervisory professor practice diplomacy school board air liquide sa chairman foreign service georgetown university royal national theatre presidentof ircgroup llc dr michle barzach dr lucy shapiro nonexecutive director glaxosmithkline nonexecutive director glaxosmithkline dr barzach member international dr shapiro ludwig professor cancer research cooperation high council chairman board department developmental biology equilibres et populations director director beckman centre molecular board project hope international consultant genetic medicine stanford university school health strategy formerly french minister medicine health family questions views share please contact us design consultancy salterbaxter csrcontactgskcomor write us product names throughout publication indicated italics csr trademarks glaxosmithkline plc subsidiaries associated companies global public policy glaxosmithkline printed uk st ives westerham press paper used great west road production document made pulps harvested fromsustainable brentford forests also using sawmill residues forest thinnings elemental middlesex tw gs chlorinefree ukwwwgskcom